Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per share. Piper Sandler emphasizes Abbott’s attractive valuation, strong financial outlook,
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those losses by quickly developing and marketing COVID-19 diagnostic tests.
How Does Abbott Laboratories (ABT) Stack Up Against Its Industry Peers?
Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low of $114.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Key Insights The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) on September 13 and set a
Fintel on MSN18h
Piper Sandler Initiates Coverage of Abbott Laboratories (ABT) with Overweight Recommendation
Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Law1d
Who Got the Work: O'Melveny Set to Defend Abbott Labs in Digital Privacy Class Action
O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other ...
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
KERA News50m
Abbott visits Fort Worth to swear in slate of new Texas business court judges
With hands raised and in black robes, Gov. Greg Abbott swore in 10 judges to the newly created statewide business courts at a ...
Abbott bowls Hants to win over Worcestershire
Hampshire move up to second in the County Championship as Kyle Abbott's 5-36 seals a 235-run win over Worcestershire.
Zacks.com on MSN22h
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...